$BIAF
bioAffinity Technologies, Inc. Stock $biaf

$biaf Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223010186 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$921.00	$2.350K	$4.803K
YoY Change
Cost Of Revenue	$87.00	$180.00	$467.00
YoY Change
Gross Profit	$834.00	$2.170K	$4.336K
YoY Change
Gross Profit Margin	90.55%	92.34%	90.28%
Selling, General & Admin	$1.170M	$1.429M	$2.727M
YoY Change	231.77%	62.21%	209.62%
% of Gross Profit	140234.89%	65836.87%	62893.7%
Research & Development	$369.6K	$197.3K	$1.100M
YoY Change	-1.31%	-85.12%	-17.05%
% of Gross Profit	44318.59%	9089.86%	25369.0%
Depreciation & Amortization	$22.00K	$7.330K	$10.18K
YoY Change	2015.38%	130.5%	111.2%
% of Gross Profit	2637.89%	337.79%	234.78%
Operating Expenses	$1.559M	$1.626M	$4.015M
YoY Change	114.4%	-26.32%	81.95%
Operating Profit	-$1.558M	-$1.624M	-$4.011M
YoY Change	114.29%		81.76%
Interest Expense	$37.00K	-$50.84K	$2.533M
YoY Change	-104.98%	-98.83%	-158.13%
% of Operating Profit
Other Income/Expense, Net	$37.00K		-$4.141M
YoY Change	-103.23%
Pretax Income	-$1.521M	-$1.675M	-$8.152M
YoY Change	3.48%	-73.52%	28.89%
Income Tax	$11.82K	$0.00	$2.459K
% Of Pretax Income
Net Earnings	-$1.533M	-$1.675M	-$8.154M
YoY Change	4.13%	-73.53%	28.89%
Net Earnings / Revenue	-166426.71%	-71258.72%	-169771.25%
Basic Earnings Per Share	-$0.18		-$1.81
Diluted Earnings Per Share	-$0.18	-$0.37	-$1.81
COMMON SHARES
Basic Shares Outstanding	8.463M shares	8.370M shares	4.499M shares
Diluted Shares Outstanding	8.434M shares		4.499M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.769M	$11.41M	$11.41M
YoY Change	850.27%		738.85%
Cash & Equivalents	$9.800M	$11.40M	$11.41M
Short-Term Investments
Other Short-Term Assets	$441.1K	$531.9K	$531.9K
YoY Change	579.39%		599.22%
Inventory	$11.34K	$5.540K	$5.540K
Prepaid Expenses
Receivables	$11.03K	$10.49K	$10.49K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.23M	$11.96M	$11.96M
YoY Change	825.51%	731.69%	731.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$225.1K	$214.4K	$214.4K
YoY Change	6169.28%	4528.49%	4531.53%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.920K	$6.000K	$6.000K
YoY Change	-97.16%	140.0%	-42.53%
Total Long-Term Assets	$232.0K	$220.4K	$220.4K
YoY Change	-6.23%	1362.28%	1361.8%
TOTAL ASSETS
Total Short-Term Assets	$10.23M	$11.96M	$11.96M
Total Long-Term Assets	$232.0K	$220.4K	$220.4K
Total Assets	$10.46M	$12.18M	$12.18M
YoY Change	673.42%	738.23%	738.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$146.5K	$345.0K	$345.0K
YoY Change	-40.84%	49.75%	49.75%
Accrued Expenses	$481.3K	$541.9K	$541.9K
YoY Change	-74.12%	12.08%	-66.24%
Deferred Revenue
YoY Change
Short-Term Debt	$168.4K	$251.7K	$251.7K
YoY Change	-98.57%		-97.75%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$796.3K	$1.139M	$1.139M
YoY Change	-94.26%	-91.27%	-91.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$796.3K	$1.139M	$1.139M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$796.3K	$1.139M	$1.139M
YoY Change	-94.33%	-91.37%	-91.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$38.20M	-$36.70M
YoY Change		28.71%
Common Stock	$59.24K	$58.67K
YoY Change		213.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.668M	$11.04M	$11.04M
YoY Change
Total Liabilities & Shareholders Equity	$10.46M	$12.18M	$12.18M
YoY Change	673.42%	738.23%	738.23%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.533M	-$1.675M	-$8.154M
YoY Change	4.13%	-73.53%	28.89%
Depreciation, Depletion And Amortization	$22.00K	$7.330K	$10.18K
YoY Change	2015.38%	130.5%	111.2%
Cash From Operating Activities	-$1.529M	-$1.301M	-$4.071M
YoY Change	141.19%	-21.48%	98.68%
INVESTING ACTIVITIES
Capital Expenditures	$32.31K	$220.0K	$220.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$32.31K	-$220.0K	-$220.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$83.32K	-563.6K	$14.34M
YoY Change	-127.65%	-120.2%	331.2%
NET CHANGE
Cash From Operating Activities	-$1.529M	-1.301M	-$4.071M
Cash From Investing Activities	-$32.31K	-220.0K	-$220.0K
Cash From Financing Activities	-$83.32K	-563.6K	$14.34M
Net Change In Cash	-$1.645M	-2.084M	$10.05M
YoY Change	394.47%	-283.98%	686.92%
FREE CASH FLOW
Cash From Operating Activities	-$1.529M	-$1.301M	-$4.071M
Capital Expenditures	$32.31K	$220.0K	$220.0K
Free Cash Flow	-$1.561M	-$1.521M	-$4.291M
YoY Change	146.28%	-8.2%	109.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2021	us-gaap	Gross Profit GrossProfit		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001712762
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Inventory Net InventoryNet		usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2022Q4	BIAF	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent		usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022Q4	BIAF	Paycheck Protection Program Loan Noncurrent PaycheckProtectionProgramLoanNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables		usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	BIAF	Payment Of Return Of Capital From Stock Split PaymentOfReturnOfCapitalFromStockSplit		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021Q4	BIAF	Deferred Tax Assets Capitalized Re Costs DeferredTaxAssetsCapitalizedReCosts		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41463
CY2022	dei	Entity Registrant Name EntityRegistrantName	bioAffinity Technologies, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5211056
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	22211 W Interstate 10
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1206
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Antonio
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78257
CY2022	dei	City Area Code CityAreaCode	(210)
CY2022	dei	Local Phone Number LocalPhoneNumber	698-5334
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	0	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8462953	shares
CY2022	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2022	dei	Auditor Location AuditorLocation	New York, New York
CY2022	dei	Auditor Firm AuditorFirmId	100
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11413759	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1360638	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	10489	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1530	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5540	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531899	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	76065	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11961687	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1438233	usd
CY2021Q4	us-gaap	Deferred Costs DeferredCosts	7942	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214438	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4633	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2500	usd
CY2022Q4	us-gaap	Assets Assets	12182125	usd
CY2021Q4	us-gaap	Assets Assets	1453308	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	345042	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	230407	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	541894	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	483501	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1121392	usd
CY2021Q4	BIAF	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent	52074	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	251746	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	11152151	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1138682	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13039525	usd
CY2021Q4	BIAF	Paycheck Protection Program Loan Noncurrent PaycheckProtectionProgramLoanNoncurrent	160184	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1138682	usd
CY2021Q4	us-gaap	Liabilities Liabilities	13199709	usd
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	756558	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	756558	shares
CY2022Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	usd
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	5825648	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4044318	usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285714	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285714	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8381324	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8381324	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2677140	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2677140	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	58669	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	18740	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47652242	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12703896	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36667468	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28513355	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15790719	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12182125	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1453308	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4803	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	467	usd
CY2022	us-gaap	Gross Profit GrossProfit	4336	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1142777	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1007476	usd
CY2022	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	145546	usd
CY2021	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	130475	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2727071	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1068871	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4015394	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2206822	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4011058	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2206822	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	46708	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	424	usd
CY2022	us-gaap	Interest Expense InterestExpense	2532640	usd
CY2021	us-gaap	Interest Expense InterestExpense	1001854	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	239200	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4080339	usd
CY2022	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-1866922	usd
CY2021	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	724928	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8151654	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6324463	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2459	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1950	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8154113	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6326413	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.81
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.36
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4498964	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2675270	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-15072863	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	43012	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4080339	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	739602	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	745604	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6326413	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15790719	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	248592	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	462344	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	-185	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	352250	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6027414	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4044318	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	16065332	usd
CY2022	BIAF	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	7713310	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74900	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8154113	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8154113	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6326413	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10182	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4817	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	2055627	usd
CY2021	us-gaap	Accretion Expense AccretionExpense	480574	usd
CY2022	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-1866922	usd
CY2021	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	724928	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	248592	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	43012	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4080339	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	239200	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	8959	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5540	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	492753	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	34990	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	114635	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	39020	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	66335	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	107744	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	440485	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	521047	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4070845	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2048978	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	219987	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-219987	usd
CY2022	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	555148	usd
CY2021	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	212258	usd
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	269983	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	724000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3295000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	425000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6027414	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7713310	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	74900	usd
CY2022	BIAF	Payment Of Return Of Capital From Stock Split PaymentOfReturnOfCapitalFromStockSplit	185	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	55651	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	180750	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14343953	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3326508	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10053121	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1277530	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1360638	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	83108	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11413759	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1360638	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2459	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1950	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	30637	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	4044318	usd
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	16065332	usd
CY2022	BIAF	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	352250	usd
CY2021	BIAF	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	74556	usd
CY2022	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes	462344	usd
CY2021	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes	739602	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-7 reverse stock split
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36700000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11400000	usd
CY2022Q4	BIAF	Total Assets Percent TotalAssetsPercent	0.93	pure
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zPIEneKpwH4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zZJV0enLwDSe">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the fair value of the Company’s Common Stock used to measure stock-based compensation for options granted to employees and nonemployees; the valuation allowance on the Company’s deferred tax assets; and the fair value of the convertible notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1800000	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	8000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zg1AibJ57Dtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zcF9Nd1d2Hk6">Concentration of Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zkl7xc6Pa3h9" title="Insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2022	us-gaap	Advertising Expense AdvertisingExpense	3000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	0	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5456344	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5883062	shares
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1100000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1000000.0	usd
CY2021Q4	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	55081	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	119773	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4219	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531899	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	76065	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_845_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zcknwUcIgdji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zIZdl4eI04Ed">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified to conform to current year presentation. The Company reclassified patent and annuity costs of approximately $<span id="xdx_903_eus-gaap--FiniteLivedPatentsGross_iI_c20220101__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zHpvf57I40N7" title="Patent and annuity costs">236,000</span> and $<span id="xdx_90D_eus-gaap--FiniteLivedPatentsGross_iI_c20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zjOhHINvotE4" title="Patent and annuity costs">188,000</span> from research and development to selling, general and administrative for the years ended December 31, 2022, and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>bioAffinity Technologies, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></p> <p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2022 and 2021</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	340078	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	16765	usd
CY2022Q4	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	72048	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	483618	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	263631	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	269180	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	258998	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214438	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4633	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10182	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4817	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	340680	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	277185	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	144440	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	166069	usd
CY2022Q4	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	50922	usd
CY2021Q4	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	39481	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5852	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	766	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	541894	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	483501	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	11152151	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	11152151	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	700000	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	3300000	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	9767461	usd
CY2021	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issue Of Convertible Notes Payable FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssueOfConvertibleNotesPayable	3295000	usd
CY2021	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Debt Discount For Warrant Issued FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDebtDiscountForWarrantIssued	-1665956	usd
CY2021	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accretion Of Debt Issuance Costs FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDebtIssuanceCosts	480574	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-724928	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	11152151	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	724000	usd
CY2022	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Repayment Of Convertible Notes Payable FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfConvertibleNotesPayable	-100000	usd
CY2022	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Debt Discount For Warrant Issued FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDebtDiscountForWarrantIssued	-870245	usd
CY2022	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accretion Of Debt Issuance Costs FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDebtIssuanceCosts	2055627	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	1866922	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3	-325000	usd
CY2022	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion Of Convertible Notes Payable FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfConvertibleNotesPayable	-14503455	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	8781957	usd
CY2021Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	1185382	usd
CY2021Q4	BIAF	Fair Value Adjustments On Convertible Notes Payables FairValueAdjustmentsOnConvertibleNotesPayables	3555576	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	11152151	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	65000	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	52000	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-7 reverse stock split
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285714	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8381324	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1100000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	1100000	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	248592000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	43012000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	824104	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.10
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	79273	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.49
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	24997	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.70
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	878380	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.12
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7142	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.20
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	64848	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.16
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	14282	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.95
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	806392	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.33
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	164255	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	800838	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.31
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	164255	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	79273	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.23
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7142	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.84
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	64848	shares
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	75000	usd
CY2022Q4	us-gaap	Share Price SharePrice	4.62
CY2021Q4	us-gaap	Share Price SharePrice	3.79
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.639	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.728	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0220	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0114	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q3	us-gaap	Class Of Warrant Or Right Expense Or Revenue Recognized ClassOfWarrantOrRightExpenseOrRevenueRecognized	Pursuant to the underwriting agreement dated August 31, 2022, (the “Underwriting Agreement”) between the Company and WallachBeth Capital, LLC, as representative of the underwriters (the “Underwriters”), and solely for purposes of covering any over-allotments made in connection with our IPO, we granted the Underwriters an option to purchase up to an additional 192,390 shares of Common Stock at the Offering Price per Unit less $0.02, and/or up to 192,390 Tradeable Warrants at $0.01 per Tradeable Warrant, and/or up to 192,390 Non-tradeable Warrants at $0.01 per Non-tradeable Warrant, or any combination of additional shares of Common Stock, Tradeable Warrants, and Non-tradeable Warrants representing in the aggregate up to 15% of the number of Units sold in the IPO (the “Over-Allotment Option”). The Over-Allotment Option was exercisable for a period of 45 days from the date of our Final Prospectus
CY2022	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	500000	usd
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2100000	usd
CY2021	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	700000	usd
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	500000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	18400000	usd
CY2022	BIAF	Effective Income Tax Rate Reconciliation In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationInDeferredTaxAssetsValuationAllowance	1	pure
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	800000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3871192	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3302836	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	477055	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	434645	usd
CY2022Q4	BIAF	Deferred Tax Assets Capitalized Re Costs DeferredTaxAssetsCapitalizedReCosts	260560	usd
CY2022Q4	BIAF	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	-7337	usd
CY2021Q4	BIAF	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	1099	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5708	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3974	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	443867	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	484778	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5051045	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4227332	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5051045	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4227332	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.104	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.148	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.022	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.019	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.101	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.081	pure
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	190229	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	49646	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	49646	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	70893	usd
CY2022	BIAF	Unrecognized Tax Benefits Increase Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreasesResultingFromPriorPeriodTaxPositions	110681	usd
CY2021	BIAF	Unrecognized Tax Benefits Increase Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreasesResultingFromPriorPeriodTaxPositions	-21247	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	29902	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	190229	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	49646	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.08	pure
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.20

Files In Submission

Name	View Source	Status
0001493152-23-010186-index-headers.html	Edgar Link	pending
0001493152-23-010186-index.html	Edgar Link	pending
0001493152-23-010186.txt	Edgar Link	pending
0001493152-23-010186-xbrl.zip	Edgar Link	pending
biaf-20221231.xsd	Edgar Link	pending
ex19-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_01.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
biaf-20221231_def.xml	Edgar Link	unprocessable
biaf-20221231_lab.xml	Edgar Link	unprocessable
biaf-20221231_cal.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
biaf-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIAF
bioAffinity Technologies, Inc. Stock $biaf

2023 Q1 Form 10-K Financial Statement

#000149315223010186 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF bioAffinity Technologies, Inc. Stock $biaf

2023 Q1 Form 10-K Financial Statement

#000149315223010186 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF
bioAffinity Technologies, Inc. Stock $biaf